SpinaFX is a Toronto-based medical device company developing minimally invasive, image-guided treatments for back pain due to contained herniated discs. Its lead therapy, Triojection®, delivers an ozone-oxygen mixture into the disc as an outpatient, image-guided procedure intended to reduce disc volume and related nerve pressure. Triojection is not yet approved and the company cites preliminary data suggesting potential clinical benefit. SpinaFX plans to pursue further clinical validation and regulatory approval for the therapy. The company recently closed the final tranche of its Series B, raising CAD $5.3M, with backers undisclosed. SpinaFX intends to use the proceeds to expand operations and advance development efforts.

Total raised

$4M

Funding rounds

1

Latest round

Series B

Latest activity

Dec 2024